GLP-1 RECEPTOR AGONIST AND USE THEREOF

• Main Authors: YOON Hong Chul, AN Kyung Mi, HONG Changhee, LEE Myong Jae, SHIN Jae Eui, JEONG Jin Ah, JUN Yearin, CHANG Min Whan, OH Changmok, KIM Jung Ho, YOO Yeongran, KWON Sung Wook, HONG Da Hae, JANG Eun Hye, KIM Kyeojin, KIM Jeong-geun, KIM Gunhee, JE In-gyu, PARK Jung-eun, IM A-rang, JEON Woo Jin, LEE Jin Hee, HEO Jaeho, CHOI Ji Hye, SOHN Te-ik
• Format: Patent
• Language: English; Spanish
• Published: 14.06.2022
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems. Se describen compuestos novedosos de la Fórmula Química 1, isómeros ópticos de los compuestos, y sales farmacéuticamente aceptables de los compuestos o los isómeros ópticos. Los compuestos, isómeros, y sales exhiben excelente actividad como agonistas del receptor GLP-1. En particular, estos, como agonistas del receptor GLP-1, exhiben una excelente tolerancia a la glucosa, por ende, tienen un gran potencial de ser usados como agentes terapéuticos para enfermedades metabólicas. Asimismo, exhiben una excelente seguridad farmacológica para los sistemas cardiovasculares.